Publications & Posters

Publications & Posters

Clinical Chemistry | September 14, 2015
Nucleic acid testing (NAT) has become the standard for high sensitivity in detecting low levels of virus. However, adoption of NAT can be cost prohibitive in low-resource settings where access to extreme sensitivity could be clinically advantageous for early detection of infection. We report…
Alzheimer's and Dementia |2016
Tau protein levels in plasma may be a marker of neuronal damage. We examined associations between plasma tau levels and Alzheimer's disease (AD)–related magnetic resonance imaging (MRI) and positron emission tomography (PET) neuroimaging measures among nondemented individuals.
Nature Communications | March 2016
Increased APP (amyloid precursor protein) processing causes β-amyloid (Aβ) accumulation in autosomal dominant Alzheimer's disease (AD), but it is unclear if it also affects sporadic Aβ accumulation. We tested healthy controls and patients with mild cognitive symptoms (N=331) in the BioFINDER study…
Scientific Reports | May 31, 2016
Implementation of amyloid biomarkers in clinical practice would be accelerated if such biomarkers could be measured in blood. This study analyzes plasma levels of Aβ42 and Aβ40 in a cohort of 719 individuals using a ultrasensitive Simoa platform.
ANAEROBE 2016 | July 11-14 2016
The objective of this study was to evaluate a quantitative assay using the SimoaTM technology for simultaneous detection of toxins A and B of C. difficile in human fecal samples.
Nature Reviews Neurology | September 16, 2016
Diagnostic and prognostic biomarkers for mild traumatic brain injury (TBI), also known as concussion, remain a major unmet clinical need. Moderate to severe TBI can be diagnosed definitively by clinical assessment and standard neuroimaging techniques that detect the gross damage to the brain…

This website uses cookies. By continuing to use this website you are acknowledging and agree with our cookie policy.

AgreeLearn more